U004 Dermoscopy to the Rescue! Maximizing the Power of the Dermatoscope for Diagnostic and Management Challenges in Your Patients With Skin Cancer
DESCRIPTION
Dermoscopy is crucial in the dermatologist’s everyday practice as it enhances the visualization of skin structures, thereby improving diagnostic accuracy. This non-invasive tool also provides detailed insights into various pigmentation patterns and vascular structures, which streamline management decisions. This session on dermoscopy that reviews key dermatoscopic features of melanoma variants, basal cell carcinoma subtypes, and the spectrum of squamous cell carcinoma (actinic keratosis, in situ and invasive SCC, and keratoacanthoma) will allow participants to maximize use of his/her dermatoscope for improving diagnostic confidence, tailor management decisions for isolated lesions or field cancerization, and improve patient outcomes in his/her dermatology practice.
LEARNING OBJECTIVES
Improve diagnostic accuracy of melanoma variants using characteristic dermatoscopic features and appropriately plan for management
Enhance recognition and management capabilities of basal cell carcinoma variants using dermoscopy, thereby increasing early detection and streamlining same-day treatment planning
Increase ability to identify cutaneous squamous cell neoplasms on dermoscopy and select a wide range of evidence-based surgical/non-surgical options that best suits an isolated lesion or field cancerization
SCHEDULE
7:30 AM
Not always in the textbook: unusual dermatoscopic features of melanoma variants
Kelly C Nelson, MD, FAAD
7:45 AM
The role of dermoscopy in streamlining basal cell carcinoma management
Elizabeth V. Seiverling, MD, FAAD
8:00 AM
Real-time identification and management of the spectrum of actinic keratosis to squamous cell carcinoma
Drew Arthur Emge, MD, MSc, FAAD
8:15 AM
Discussion
DIRECTOR
Drew Arthur Emge, MD, MSc, FAAD
SPEAKERS
Kelly C Nelson, MD, FAAD
Elizabeth V. Seiverling, MD, FAAD
DISCLOSURES
Drew Arthur Emge, MD, MSc, FAAD
No financial relationships exist with ineligible companies.
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.
Elizabeth V. Seiverling, MD, FAAD
Melatech – Independent Contractor(Fees);